Is CD30 an accurate diagnostic marker in lymphomas other than Hodgkin lymphoma?

FAQ published on February 3, 2016
Download Transcript Download Audio
Bruce D. Cheson, MD
Professor of Medicine
Director of Hematology Research
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Washington, DC
Is CD30 an accurate diagnostic marker in lymphomas other than Hodgkin lymphoma?
Welcome to Managing Hodgkin Lymphoma. My name is Bruce Cheson and I am deputy chief of hematology/oncology and head of hematology at Georgetown University Hospital, Lombardi Comprehensive Cancer Center. I am frequently asked, “Is CD30 an accurate diagnostic marker in lymphomas other than Hodgkin lymphoma?” CD30 is important in making the diagnosis of classical Hodgkin lymphoma, but it is also present on a number of other lymphoid malignancies, notably anaplastic large call lymphoma, which is why it has such a high response rate to brentuximab vedotin, the anti-CD30 antibody drug conjugate. But that is not the only lymphoid malignancy that expresses this antigen. For example, there are other T-cell lymphomas, including cutaneous T-cell lymphoma, and in fact there are B-cell lymphomas. About a quarter or so of diffuse large B-cell lymphomas also express CD30 and some of these patients do respond to brentuximab vedotin as well. So thank you for viewing this activity. For additional resources, please view the other educational activities on ManagingHodgkinLymphoma.com.
Last modified: February 8, 2016
Related Items by Author
What alternatives may be used to accurately stage Hodgkin lymphoma if PET-CT is not available?
Bruce D. Cheson, MD
FAQ published on March 3, 2016
What strategies can be utilized to accurately diagnose Hodgkin lymphoma in areas that lack adequate pathology?
Bruce D. Cheson, MD
FAQ published on January 11, 2016